Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. I . M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
    2. University children’s clinical hospital, gastroenterology Department, Moscow, Russia

    Keywords: UC, teenagers, course, adherence, eff ectiveness of therapy

    Abstract:The problems of ulcerative colitis (UC) in pediatric practice are the diffi culties of primary diagnosis, the severity of the course due to the greater extent of the colon lesion and the diffi culty in choosing a drug eff ect. The age of the patients determines the extent of colon lesions in UC in children. Thus, in the older age group, especially older than 15 years, characterized by a high frequency of left-sided ulcerative colitis forms in contrast to adults. The choice of therapy in children with UC depends on the severity of the condition, localization and extent of the lesion, the severity of humoral activity and the age of the child, as well as adherence (compliance) therapy. This example demonstrates that in a teenage boy ulcerative colitis had a rare localization for children, there was a violation of the recommended therapy at the beginning and dynamics of observation, which led to a relapse and progression of the disease. Low adherence to therapy signifi cantly worsened the course and prognosis of the pathological process, and therefore the quality of life of the patient.

      1. Потапов АС, Алиева ЭИ, Габрузская ТВ, Горелов АВ, Захарова ИН, Корниенко ЕА и др. Клиническая картина, диагностика и лечение язвенного колита у детей: Российский педиатрический консенсус (репринт). Вопросы современной педиатрии. 2013; 12 (3):1–9.
      2. D. Turner, F. M. Ruemmele, E. Orlanski-Meyer, Anne M. Griffi ths, Javier Martin de Carpi et al. Management of Paediatric Ulcerative Colitis, Part 1–2. An Evidence-based Guideline From European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. JPGN. V 67. 2. 2018.
      3. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric infl ammatory bowel disease:а systematic review of international trends. Inflamm Bowel Dis 2011;17: 423–39.
      4. Van Limbergen J, Russell RK, Drummond HE, et al. Defi nition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114–22.
      5. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. Th e natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009;104: 2080–8.
      6. Turner D, Muise AM. Very early onset ibd: how very diff erent ‘on average’? J Crohns Colitis 2017;11:517–8.
      7. Magro F, Gionchetti P, Eliakim R, et al. Th ird European evidencebased consensus on diagnosis and management of ulcerative colitis. Part 1: defi nitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017;11:649–70.
      8. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012;55:340–61.
      9. Aloi M, D’Arcangelo G, Pofi F, et al. Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis 2013;7: e509–15.
      10. Aloi M, D’Arcangelo G, Pofi F, et al. Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis 2013;7: e509–15.
      11. Анушенко А. О., Потапов А. С., Цымбалова Е. Г., Гордеева О. Б. Анемия при воспалительных заболеваниях кишечника у детей //Вопросы современной педиатрии. 2016. Т 15. № 2. С. 128–140.
      12. Щербаков П. Л. Воспалительные заболевания кишечника у детей: болезнь Крона и неспецифический язвенный колит //Детский доктор. 2000. № 4. С. 22–26.
      13. Harbord M, Annese V, Vavricka SR, et al. Th e fi rst European evidencebased consensus on extra-intestinal manifestations in infl ammatory bowel disease. J Crohns Colitis 2016;10:239–54.
      14. Harbord M, Annese V, Vavricka SR, et al. Th e fi rst European evidencebased consensus on extra-intestinal manifestations in infl ammatory bowel disease. J Crohns Colitis 2016;10:239–54.
      15. Яблокова Е. А., Горелов А. В., Сичинава И. В., Борисова Е. В., Полотнянко Е. Ю., Грамматопуло М. И., Каншина А. А. Течение внекишечных проявлений воспалительных заболеваний кишечника у детей. Экспериментальная и клиническая гастроэнтерология. 2016. № 8 (132). С. 62–66.
      16. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9.
      17. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–9.
      18. Sidoroff M, Kolho KL. Glucocorticoids in pediatric inflammatory bowel disease. Scand J Gastroenterol 2012;47:745–50.
      19. Romano C, Famiani A, Comito D, et al. Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. J Pediatr Gastroenterol Nutr 2010; 50: 385–9.
      20. Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (10)2010CD007698.
      21. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63:433–41
      22. Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the effi cacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Th er 2009;30:126–37.
      23. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infl iximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:391–9e1.
      24. Turner D, Griffi ths AM, Veerman G, et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infl iximab. Clin Gastroenterol Hepatol 2013;11: 1460–5.
      25. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020–4. doi: 10.1007/s10620–007–9968–0
      26. Сичинава И. В. Необходимость совершенствования системы реабилитации детей с хроническими гастродуоденитами //Фарматека. 2012. № 3. С. 60–63.
      27. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric infl ammatory bowel disease. J Pediatr Psychol. 2008;33:867–74. doi: 10.1093/jpepsy/jsn022
      28. Horváth G, Farkas K, Hollósi R, et al. Is there any association between impaired health-related quality of life and non-adherence to medical therapy in infl ammatory bowel disease? Scand J Gastroenterol. 2012;47:1298–303. doi: 10.3109/00365521.2012.703233
      29. Бузунова Ю. М., Белоусова Е. А. Приверженность к лечению пациентов с воспалительными заболеваниями кишечника. Тезисы 15-го юбилейного съезда НОГР. Экспериментальная и клиническая гастроэнтерология. 2015.В 117. 5: С 78–79.
      30. Selinger CP, Eaden J, Jones DB, et al. Modifi able factors associated with nonadherence to maintenance medication for infl ammatory bowel disease. Infl amm Bowel Dis. 2013;19: 2199–206.doi: 10.1097/MIB.0b013e31829ed8a6
      31. Sichinava I. B., Galstyan L. R., Gorelov A. V., Yablokova E. A., Krutikhina S. B., Shishov A. Y. Cr ohn’s disease: a review of literature and a description of own clinical observation//New Armenian Medical Journal. 2016. Т. 10. № 3. С. 52–57.

    Full text is published :
    Tahirova A. R., Sichinava I. V., Yablokova E. A., Tyurina E. N., Krutikhina S. B., Borisova E. V., Polotnyanko E. U., Frolkova E. V. Ulcerative colitis: features of the course and adherence to prescribed therapy in adolescents. Experimental and Clinical Gastroenterology. 2019;162(2): 125–130. (In Russ.) DOI: 10.31146/1682-8658-ecg-162-2-125-130
    Read & Download full text

    1. FRC CSC RAS, Institute of Pharmacoinformatics, Moscow, Russia
    2. Big Data Storage and Analysis Center (CCHD), Moscow State University, Moscow, Russia
    3. Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Healthcare of the Russian Federation, 2⁄1, Barrikadnaya st., Moscow, 125993, Russia

    Keywords: prebiotics, dysbiosis, systematic analysis, lactitol, Exportal

    Abstract:Lactitol is a prebiotic disaccharide that supports the functioning of lacto- and bifi dobacteria, also inhibits the growth of pathogenic fl ora. The results of transcriptome and proteomic studies have shown that lactitol is characterized by unique absorption and processing mechanisms in lactobacteriathat distinguish it from other prebiotics. In high doses (5 … 50 g/day) lactiol is used as an osmotic laxative. Lactictol enhances the detoxifi cation of the body (in particular, the excretion of ammonia and toxic amines). The detoxifi cation eff ect of lactitol, lack of lactitol’seff ect on blood lipid and glycemic profi les, lack of food intolerance and rare occurrenceof side eff ects (fl atulence, transient diarrhea when the dose is exceeded) make lactitol an important tool in the treatment of dysbiosis, liver disease and hepatic encephalopathy.

      1. Salminen S, Bouley C, Boutron-RuaultMC, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 80, Suppl. 1, 1998, p. 147–171.
      2. Grimble GK, Patil DH, Silk DB (1988).”Assimilation of lactitol, an unabsorbed disaccharide in the normal human colon”.Gut. 29 (12): 1666–1671. doi:10.1136/ gut.29.12.1666. PMC1434111. PMID3220306
      3. Torshin I. Y. Optimal dictionaries of the fi nal information on the basis of the solvability criterion and their applications in bioinformatics. Pattern Recognition and Image Analysis (Advances in Mathematical Th eory and Applications). 2013. Т. 23. № 2.С. 319–327.
      4. TorshinI.Yu., Rudakov K. V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. part 2: metric approach within the framework of the theory of classifi cation of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Th eory and Applications). 2017. Т. 27. № 2.С. 184–199.
      5. Torshin I. Y., Rudakov K. V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. part 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Th eory and Applications). 2017. Т. 27. № 1.С. 16–28.
      6. Torshin I. Y., Rudakov K. V. On metric spaces arising during formalization of problems of recognition and classifi cation.part 1: properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Th eory and Applications). 2016. С. 1.
      7. TorshinI.Yu., Rudakov K. V. On metric spaces arising during formalization of problems of recognition and classifi cation.part 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Th eory and Applications). 2016. Т. 26. № 3.С. 483–496.
      8. TorshinI.Yu., Rudakov K. V. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classifi cation. Pattern Recognition and Image Analysis (Advances in Mathematical Th eory and Applications).2015. Т. 25. № 4. С. 577–587
      9. Торшин И. Ю., Гусев Е. И., Громова О. А., Калачева А. Г., Рудаков К. В. Мировой опыт изучения эффектов омега-3 полиненасыщенных жирных кислот: влияние на когнитивный потенциал и некоторые психические расстройства. Журнал неврологии и психиатрии им. C. C. Корсакова. 2011. Т. 111. № 11. С. 79–86.
      10. Ballongue J, Schumann C, Quignon P. Eff ects of lactulose and lactitol on colonic microfl ora and enzymatic activity.Scand J Gastroenterol Suppl. 1997;222:41–4. doi: 10.1080/00365521.1997.11720716. PubMed ID:9145445
      11. Tarao K, Tamai S, Ito Y, Okawa S, Hayashi M. [Eff ects of lactitol on fecal bacterial fl ora in patients with liver cirrhosis and hepatic encephalopathy].Nihon ShokakibyoGakkaiZasshi. 1995 Jul;92(7):1037–50. PubMed ID:7643458
      12. Andersen JM, Barrangou R, Hachem MA, Lahtinen SJ, Goh YJ, Svensson B, Klaenhammer TR. Transcriptional analysis of prebiotic uptake and catabolism by Lactobacillus acidophilus NCFM.PLoS One. 2012;7(9): e44409. doi: 10.1371/journal.pone.0044409. Epub 2012 Sep 19. PubMed ID:23028535
      13. Majumder A, Sultan A, Jersie-Christensen RR, Ejby M, Schmidt BG, Lahtinen SJ, Jacobsen S, Svensson B. Proteome reference map of Lactobacillus acidophilus NCFM and quantitative proteomics towards understanding the prebiotic action of lactitol.Proteomics. 2011 Sep;11(17):3470–81. doi: 10.1002/pmic.201100115. Epub 2011 Jul 27. PubMed ID:21751373
      14. Natah SS, Hussien KR, Tuominen JA, Koivisto VA. Metabolic response to lactitol and xylitol in healthy men. Am J ClinNutr. 1997 Apr;65(4):947–50. doi: 10.1093/ ajcn/65.4.947. PubMed ID:9094877
      15. Olli K, Saarinen MT, Forssten SD, Madetoja M, Herzig KH, Tiihonen K. Independent and Combined Eff ects of Lactitol, Polydextrose, and Bacteroidesthetaiotaomicron on Postprandial Metabolism and Body Weight in Rats Fed a High-Fat Diet.FrontNutr. 2016 Jun 8;3:15. doi: 10.3389/ fnut.2016.00015. eCollection 2016. PubMed ID:27376068
      16. Shimomura Y, Maeda K, Nagasaki M, Matsuo Y, Murakami T, Bajotto G, Sato J, Seino T, Kamiwaki T, Suzuki M. Attenuated response of the serum triglyceride concentration to ingestion of a chocolate containing polydextrose and lactitol in place of sugar.BiosciBiotechnolBiochem. 2005 Oct;69(10):1819–23. PubMed ID:16244429
      17. Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia.Adv Drug Deliv Rev. 2015 Aug 1;90:55–68. doi: 10.1016/j.addr.2015.04.009. Epub 2015 Apr 17. PubMed ID:25895618
      18. Watanabe M, Ozaki T, Hirata Y, Yamamoto O, Niida H, Ueda F, Yoshikuni Y, Kimura K. Mechanism for lowering blood ammonia levels by lactitol.Jpn J Pharmacol. 1995 Apr;67(4):369–74. PubMed ID:7650870
      19. Mushiroi T, Shibahara R, Ukai Y, Hirata Y, Ozaki T, Watanabe M, Kimura K. [Lactitol suppresses the disturbance of consciousness caused by experimentally induced hepatic encephalopathy in rats: an EEG study].Nihon YakurigakuZasshi. 1995 Feb;105(2):111–9. PubMed ID:7737591
      20. Masini A, Efrati C, Merli M, Attili AF, Amodio P, Ceccanti M, Riggio O. Eff ect of lactitol on blood ammonia response to oral glutamine challenge in cirrhotic patients: evidence for an eff ect of nonabsorbable disaccharides on small intestine ammonia generation.Am J Gastroenterol. 1999 Nov;94(11):3323–7. doi: 10.1111/j.1572– 0241.1999.01546.x. PubMed ID:10566738
      21. Iwakura K, Tamura H, Watanabe M, Sumi N. [Mutagenicity studies of lactitol (NS-4)].J Toxicol Sci. 1994 Nov;19 Suppl 3:487–97. PubMed ID:7837301
      22. Ninomiya H, Nishikawa K, Ide Y, Kondo J, Kishida K, Yamashita Y, Watanabe M, Sumi N. [Reproductive and developmental toxicity studies of lactitol (NS-4) (4)— Perinatal and postnatal study in rats by oral administration].J Toxicol Sci. 1994 Nov;19Suppl 3:471–85. PubMed ID:7837300
      23. Tesh JM, Ross FW, Wightman TJ, Wilby OK, Weith A, Watanabe M, Sumi N. [Reproductive and developmental toxicity studies of lactitol (NS-4) (3)—Teratogenicity study in rabbits by oral administration].J Toxicol Sci. 1994 Nov;19 Suppl 3:463–70. PubMed ID:7837299
      24. Nagata R, Onishi M, Okasaki K, Hamasu Y, Sumi N. [Single dose toxicity study of lactitol (NS-4) in dogs].J Toxicol Sci. 1994 Nov;19 Suppl 3:301–4. PubMed ID:7837292
      25. Oku T, Nakamura S, Ichinose M. Maximum permissive dosage of lactose and lactitol for transitory diarrhea, and utilizable capacity for lactose in Japanese female adults.JNutrSciVitaminol (Tokyo). 2005 Apr;51(2):51–7. PubMed ID:16022189
      26. Oku T, Nakamura S. Th reshold for transitory diarrhea induced by ingestion of xylitol and lactitol in young male and female adults.JNutrSciVitaminol (Tokyo). 2007 Feb;53(1):13–20. PubMed ID:17484374
      27. Ardatskaya M. D., Butorova L. I., Grigorieva Yu.V., Loginov V. A., Loshchinina Yu. N., Cheremushkin S. V. Clinical– metabolic effi ciency of lactitol in the therapy of chronic constipation (results of the non-interventional prospective observation program “Osmoaid”). Experimental and Clinical Gastroen-terology. 2018;150(2): 149–160.
      28. Chen C, Li L, Wu Z, Chen H, Fu S. Eff ects of lactitol on intestinal microfl ora and plasma endotoxin in patients with chronic viral hepatitis.J Infect. 2007 Jan;54(1):98– 102. doi: 10.1016/j.jinf.2005.11.013. Epub 2006 Oct 16. PubMed ID:17049992
      29. Festi D, Marasco G, Ravaioli F, Colecchia A. [Hepatic encephalopathy].RecentiProg Med. 2016 Jul;107(7):378–85. doi: 10.1701/2318.24932. PubMed ID:27571468
      30. Pai CH, Huang YS, Jeng WC, Chan CY, Lee SD. Treatment of porto-systemic encephalopathy with lactitolverus lactulose: a randomized controlled study.Zhonghua Yi XueZaZhi (Taipei). 1995 Jan;55(1):31–6. PubMed ID:7712392
      31. Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis.Hepatology. 2016 Sep;64(3):908–22. doi: 10.1002/hep.28598. Epub 2016 May 20. PubMed ID:27081787
      32. Yanahira S, Morita M, Aoe S, Suguri T, Nakajima I, Deya E. Effects of lactitol-oligosaccharides on the intestinal microfl ora in rats.JNutrSciVitaminol (Tokyo). 1995 Feb;41(1):83–94. PubMed ID:7616329
      33. Riggio O, Varriale M, Testore GP, Di Rosa R, Di Rosa E, Merli M, Romiti A, Candiani C, Capocaccia L. Eff ect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.JClinGastroenterol. 1990 Aug;12(4):433–6. PubMed ID:2398251
      34. Makivuokko H, Forssten S, Saarinen M, Ouwehand A, Rautonen N. Synbiotic eff ects of lactitol and Lactobacillus acidophilus NCFM in a semi-continuous colon fermentation model.Benef Microbes. 2010 Jun;1(2):131–7. doi: 10.3920/BM2009.0033. PubMed ID:21840801
      35. Bjorklund M, Ouwehand AC, Forssten SD, Nikkila J, Tiihonen K, Rautonen N, Lahtinen SJ. Gut microbiota of healthy elderly NSAID users is selectively modifi ed with the administration of Lactobacillus acidophilus NCFM and lactitol.Age (Dordr). 2012 Aug;34(4):987–99. doi: 10.1007/s11357–011–9294–5. Epub 2011 Aug 19. PubMed ID:21853265
      36. Finney M, Smullen J, Foster HA, Brokx S, Storey DM. Effects of low doses of lactitol on faecalmicrofl ora, pH, short chain fatty acids and gastrointestinal symptomology.Eur J Nutr. 2007 Sep;46(6):307–14. doi: 10.1007/s00394–007– 0666–7. Epub 2007 Jul 11. PubMed ID:17623227
      37. Piva A, Prandini A, Fiorentini L, Morlacchini M, Galvano F, Luchansky JB. Tributyrin and lactitol synergistically enhanced the trophic status of the intestinal mucosa and reduced histamine levels in the gut of nursery pigs.JAnim Sci. 2002 Mar;80(3):670–80. PubMed ID:11890403
      38. Yanahira S, Morita M, Aoe S, Suguri T, Takada Y, Miura S, Nakajima I. Eff ects of lactitol-oligosaccharides on calcium and magnesium absorption in rats.JNutrSciVitaminol (Tokyo). 1997 Feb;43(1):123–32. PubMed ID:9151246
      39. Su L, Huang Y, Zhu Y, Xia L, Wang R, Xiao K, Wang H, Yan P, Wen B, Cao L, Meng N, Luan H, Liu C, Li X, Xie L. Discrimination of sepsis stage metabolic profi les with an LC/MS-MS-based metabolomics approach.BMJ Open Respir Res. 2014 Dec 10;1(1): e000056. doi: 10.1136/ bmjresp-2014–000056. eCollection 2014. PubMed ID:25553245
      40. Grenby TH. Latest state of research on lactitol and dental caries.Int Dent J. 1989 Mar;39(1):25–32. PubMed ID:2649439
      41. Grenby TH, Phillips A. Dental and metabolic eff ects of lactitol in the diet of laboratory rats.Br J Nutr. 1989 Jan;61(1):17–24. PubMed ID:2923853
      42. Schafer C. [Food intolerances caused by enzyme defects and carbohydrate malassimiliations: Lactose intolerance and Co].BundesgesundheitsblattGesundheitsforschungGesundheitsschutz. 2016 Jun;59(6):764–70. doi: 10.1007/s00103–016–2359-y. PubMed ID:27188621
      43. Prasad VG, Abraham P. Management of chronic constipation in patients with diabetes mellitus.Indian J Gastroenterol. 2017 Jan;36(1):11–22. doi: 10.1007/s12664– 016–0724–2. Epub 2016 Dec 17. PubMed ID:27987136
      44. Maydeo A. Lactitol or lactulose in the treatment of chronic constipation: result of a systematic.J Indian Med Assoc. 2010 Nov;108(11):789–92. PubMed ID:21510584
      45. Miller LE, Tennila J, Ouwehand AC. Effi cacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis.ClinExpGastroenterol. 2014 Jul 12;7:241–8. doi: 10.2147/CEG.S58952. eCollection 2014. PubMed ID:25050074
      46. Roberfroid M. Prebiotics: Th e Concept Revisited// J. Nutr. 2007, 137 (3):830–837.
      47. Инструкция по медицинскому применению препарата Экспортал рег. № : ЛСР-003898/07–28112018
      48. Артюхова С. И., Гаврилова Ю. А. Использование лактитола в биотехнологии функциональных продуктов питания //Современные наукоемкие технологии. – 2013. – № . 3. – С. 87–88.

    Full text is published :
    Gromova O. A., Torshin I. Yu., Maximov V. A., Gromov A. N., Rudakov K. V. Systematic analysis of lactitol studies. Experimental and Clinical Gastroenterology. 2019;162(2): 131–142. (In Russ.) DOI: 10.31146/1682-8658-ecg-162-2-131-142
    Read & Download full text

    1. RUDN University, Moscow, Russia
    2. National Medical Research Center of Radiology, RF, Moscow, Russia
    3. GBUZ Moscow Clinical Research Center named after A. S. Loginov DZM, 111123, Moscow, Russia

    Keywords: iron defi ciency, iron defi ciency syndrome, infl ammatory bowel disease, treatment of anemia, sucrosomial iron, intravenous iron

    Abstract:The article describes the most common iron defi ciency syndromes (IDS) in infl ammatory bowel disease (IBD) and presents the modern principles of diff erential diagnosis of gastrointestinal disease, the advantages and disadvantages of standard methods for the correction of Iron-Defi ciency (ID) and anemia in this group of patients. The authors give a circumstantial outline of their own data of examination and treatment of 77 patients with IBD and anemia, and prove the necessity of compulsory ferritin serum (FS) testing as the most important diff erential marker of the IDs., Inadequate production of erythropoietin as the main cause of anemia has been proven in 15% of patients with high FS values. On the contrary, the necessity of mandatory use of iron preparations in management of anemia was determined in 85% of patients. The high effi ciency and safety of sucrosomial iron are proven in patients with IBD and anemia. The eff ectiveness of this method shows the normalization of hemoglobin in 68% of patients within 3 months. In contrast, intravenous iron administered during the inpatient treatment period is not suffi ciently eff ective in this category of patients, which requires the continuation of outpatient therapy with preparations of sucrosomial iron. Conclusions: Based on the obtained data and international experience, there was formulated and substantiated the algorithm of diff erentiated therapy of IDS in patients with a mild form of IBD.

      1. Filmann N., et al. Prevalence of anemia in infl ammatory bowel diseases in European countries: a systematic review and individual data meta-analysis. Infl ammatory Bowel Diseases, 2014; 20 (5): 936–45.
      2. Testa A. et al. Th e burden of anemia in patients with infl ammatory bowel diseases. Digestive and Liver Disease, 2016; 48 (3): 267–70.
      3. Cronin C.C., Shanahan F. Anemia in patients with chronic infl ammatory bowel disease. Am J Gastroenterol, 2001; 96: 2296–98.
      4. Pizzi L.T., Weston C. M., Goldfarb N. I., Moretti D., Cobb N., Howell J. B., Infantolino A., Dimarino A. J., Cohen S. Impact of chronic conditions on quality of life in patients with infl ammatory bowel disease. Infl amm Bowel Dis, 2006; 12: 47–52.
      5. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in infl ammatory bowel disease: a systematic review of the literature. Am J Med. 2004; 116. Suppl 7A: 44S-49S.
      6. Gomollón F., Gisbert J. Anemia and infl ammatory bowel diseases. World J Gastroenterol, 2009; 15 (37): 4659–65.
      7. Pratt JJ, Khan KS. Non-anaemic iron defi ciency – a disease looking for recognition of diagnosis: a systematic review. European Journal of Haematology, 2016; 96: 618–28.
      8. Vijverman A., Piront P., Belaiche J., Louis E. Evolution of the prevalence and characteristics of anemia in infl ammatory bowel diseases between 1993 and 2003. Acta Gastroenterol Belg, 2006; 69: 1–4.
      9. Dignass A.U., Gasche C., Bettenworlh D. et al. European Crohnis and Colitis Organisation [ECCO]. European consensus on the diagnosis and management of iron defi ciency and anemia in infl ammatory diseases. J Crohns Colitis, 2015; 9: 211–22.
      10. Uritski R., Barshack I., Bilkis I., Ghebremeskel K., Reifen R. Dietary iron aff ects infl ammatory status in a rat model of colitis. J Nutr. 2004; 134 (9): 2251–55.
      11. Goodnough L.T., Nissenson A. R. Anemia and its clinical consequences in patients with chronic diseases. Am J Med, 2004; 116.
      12. Rukavitsyn O. A. Anemia of chronic diseases: the important aspects of pathogenesis and treatment.Oncohematology. 2016;11(1):37–46.
      13. Gisbert J.P., F. Gomollon. Common misconceptions in the diagnosis and management of anemia in infl ammatory bowel disease // Am J Gastroenterol. 2008. Vol. 103 (5). Р. 1299–1307.
      14. Chistyakova A.V., Stuklov N. I., Pivnik A. V. Iron defi ciency anemia diagnosis and treatment approaches in gastroenterological patients. RMJ, 2015; 13: 781–84.
      15. Auerbach M., Adamson J. W. How we diagnose and treat iron defi ciency anemia. American journal of hematology, 2016; 91: 31–38.
      16. Cancelo-Hidalgo M.J., Castelo-Branco C., Palacios S., et al. Tolerability of diff erent oral iron supplements: a systematic review. Curr Med Res Opin, 2013; 29: 291.
      17. Gasché C., Reinisch W., Lochs H., Parsaei B., Bakos S., Wyatt J., Fueger G. F., Gangl A. Anemia in Crohn’s disease. Importance of inadequate erythropoietin production and iron defi ciency. Dig Dis Sci, 1994; 39: 1930–34.
      18. Dignass A.U., et al. European consensus on the diagnosis and management of iron defi ciency and anemia in infl ammatory bowel diseases. J Crohns Colitis, 2015; 9 (3): 211–22.
      19. Tobu M., Iqbal O., Fareed D., et al. Erythropoietin-induced thrombosis as a result of increased infl ammation and thrombin activatable fi brinolytic inhibitor. Clin Appl Th romb Hemost, 2004; 10: 225–32.
      20. Koutroubakis I.E., Karmiris K., Makreas S., Xidakis C., Niniraki M., Kouroumalis E. A. Eff ectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with infl ammatory bowel disease and refractory anaemia: a pilot study. Eur J Gastroenterol Hepatol, 2006; 18: 421–25.
      21. Kulnigg S., Gasche C. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Th er, 2006; 24: 1507–23.
      22. Tarantino G., Brilli E., Zambito Y., Giordano G., Equitani F. Sucrosomial Iron: A New Highly Bioavaible Oral Iron Supplement. Blood, 2015; 126: 4561.

    Full text is published :
    Stuklov N. I., Basiladze I. G., Kovalchuk M. S., Pivnik A. V., Knyazev O. V., Parfenov A. I. New options in management of Iron-Defi ciency syndromes in Infl ammatory Bowel Disease Experimental and Clinical Gastroenterology. 2019;162(2): 143–150. (In Russ.) DOI: 10.31146/1682-8658-ecg-162-2-143-150
    Read & Download full text

    1. FRC CSC RAS, Institute of Pharmacoinformatics, 119333, Moscow, Vavilova, 42, Russia
    2. Big Data Storage and Analysis Center (CCHD), Moscow State University, Moscow, Russia
    3. Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
    4. Federal State Budget Educational Institution of Higher Education “Northern State Medical University” of the Ministry of Healthcare of the Russian Federation, 163000, Arkhangelsk, Troitskiy Ave., 51

    Keywords: lactobacilli, probiotics, prebiotics, L. casei I-1572, Enterolactis

    Abstract:The eff ectiveness of probiotics is strain-specifi c. This paper presents the results of a systematic analysis of the promising lactobacterial strain Lactobacillus paracasei CNCM I-1572 (L. casei DG; L. paracasei DG). L. casei DG well survives in the conditions of the stomach and intestines, supports the benefi cial microbiota and inhibits the growth of pathogenic bacteria, exhibits a therapeutic eff ect in ulcerative colitis, eradication of H. pylori, diverticular bowel disease, and irritable bowel syndrome.

      1. Sender, R; Fuchs, S; Milo, R. Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell. 2016, 164 (3): 337–40. doi:10.1016/j.cell.2016.01.013. PMID26824647.
      2. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics.Adv Biochem Eng Biotechnol. 2008;111:1– 66. doi: 10.1007/10_2008_097. PMID:18461293
      3. Folkers BL, Schuring C, Essmann M, Larsen B. Quantitative real time PCR detection of Clostridium diffi cile growth inhibition by probiotic organisms.N Am J Med Sci. 2010 Jan;2(1):5–10. doi: 10.4297/najms.2010.15. PMID:22624106
      4. Folkers BL, Schuring C, Essmann M, Larsen B. Quantitative real time PCR detection of Clostridium diffi cile growth inhibition by probiotic organisms.N Am J Med Sci. 2010 Jan;2(1):5–10. doi: 10.4297/najms.2010.15. PMID:22624106
      5. Jungersen M, Wind A, Johansen E, Christensen JE, Stuer-Lauridsen B, Eskesen D. Th e Science behind the Probiotic Strain Bifi dobacterium animalis subsp. lactis BB-12((R)).Microorganisms. 2014 Mar 28;2(2):92–110. doi: 10.3390/microorganisms2020092. PMID:27682233
      6. Dolatkhah N, Hajifaraji M, Abbasalizadeh F, Aghamohammadzadeh N, Mehrabi Y, Abbasi MM. Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial.J Health Popul Nutr. 2015 Nov 25;33:25. doi: 10.1186/s41043–015– 0034–9. PMID:26825666
      7. О. А. Громова, И. Ю. Торшин, Н. К. Тетруашвили, В. Н. Серов. Систематический анализ клинической эффективности штамм-специфичных эффектов пробиотиков с докозогексаеновой кислотой для использования во время беременности и в период кормления, Вопросы гинекологии, акушерства и перинатологии, № 3, 2019.
      8. Arioli S, Koirala R, Taverniti V, Fiore W, Guglielmetti S. Quantitative Recovery of Viable Lactobacillus paracasei CNCM I-1572 (L.casei DG(R)) Aft er Gastrointestinal Passage in Healthy Adults.Front Microbiol. 2018 Aug 2;9:1720. doi: 10.3389/fmicb.2018.01720. eCollection 2018. PubMed ID:30116228
      9. Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM, Valsecchi C, Tagliacarne C, Fiore W, Bellini M, Bertani L, Gambaccini D, Cicala M, Germana B, Vecchi M, Pagano I, Barbaro MR, Bellacosa L, Stanghellini V, Barbara G. Eff ect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial.United European Gastroenterol J. 2018 May;6(4):604–613. doi: 10.1177/2050640617736478. Epub 2017 Oct 8. PubMed ID:29881616
      10. Radicioni M, Koirala R, Fiore W, Leuratti C, Guglielmetti S, Arioli S. Survival of L.casei DG((R)) (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population.Eur J Nutr. 2018 Nov 29. pii: 10.1007/s00394–018–1860–5. doi: 10.1007/ s00394–018–1860–5. PubMed ID:30498868
      11. Guida F, Turco F, Iannotta M, De Gregorio D, Palumbo I, Sarnelli G, Furiano A, Napolitano F, Boccella S, Luongo L, Mazzitelli M, Usiello A, De Filippis F, Iannotti FA, Piscitelli F, Ercolini D, de Novellis V, Di Marzo V, Cuomo R, Maione S. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice.Brain Behav Immun. 2018 Jan;67:230–245. doi: 10.1016/j.bbi.2017.09.001.
      12. Zambori C, Morvay AA, Sala C, Licker M, Gurban C, Tanasie G, Tirziu E. Antimicrobial eff ect of probiotics on bacterial species from dental plaque.J Infect Dev Ctries. 2016 Mar 31;10(3):214–21. doi: 10.3855/ jidc.6800.
      13. Ferrario C, Taverniti V, Milani C, Fiore W, Laureati M, De Noni I, Stuknyte M, Chouaia B, Riso P, Guglielmetti S. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults.J Nutr. 2014 Nov;144(11):1787–96. doi: 10.3945/jn.114.197723.
      14. Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F. Low effi cacy of levofl oxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol. 2015 Jun 7;21(21):6698–705. doi: 10.3748/wjg.v21.i21.6698.
      15. Tursi A, Brandimarte G, Giorgetti GM, Modeo ME. Eff ect of Lactobacillus casei supplementation on the eff ectiveness and tolerability of a new second-line 10day quadruple therapy aft er failure of a fi rst attempt to cure Helicobacter pylori infection. Med Sci Monit. 2004 Dec;10(12): CR662–6. PMID: 15567983.
      16. Turco F, Andreozzi P, Palumbo I, Zito FP, Cargiolli M, Fiore W, Gennarelli N, De Palma GD, Sarnelli G, Cuomo R. Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective eff ects of L. casei DG(R) (Lactobacillus paracasei CNCM I-1572).United European Gastroenterol J. 2017 Aug;5(5):715–724. doi: 10.1177/2050640616684398. Epub 2016 Dec 11.
      17. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon.Hepatogastroenterology. 2008 May-Jun;55(84):916–20. PubMed ID:18705297
      18. Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G, Rodino S, D’Amico T, Sacca N, Portincasa P, Capezzuto E, Lattanzio R, Spadaccini A, Fiorella S, Polimeni F, Polimeni N, Stoppino V, Stoppino G, Giorgetti GM, Aiello F, Danese S. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double-blind, randomised, placebo-controlled study.Aliment Pharmacol Th er. 2013 Oct;38(7):741–51. doi: 10.1111/apt.12463. Epub 2013 Aug 19. PubMed ID:23957734
      19. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study.J Clin Gastroenterol. 2006 Apr;40(4):312–6. doi: 10.1097/01.mcg.0000210092.77296.6d. PubMed ID:16633103
      20. Compare D, Rocco A, Coccoli P, Angrisani D, Sgamato C, Iovine B, Salvatore U, Nardone G. Lactobacillus casei DG and its postbiotic reduce the infl ammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome.BMC Gastroenterol. 2017 Apr 14;17(1):53. doi: 10.1186/s12876–017–0605-x. PubMed ID:28410580

    Full text is published :
    Torshin I. Yu., Gromova O. A., Maksimov V. A., Zacharova I. N., Malavskaiya S. I. Analysis of the strain-specifi c eff ects of lactobacilli L. casei DG (L. paracasei CNCM I-1572) and the possibility of their use in clinical practice. Experimental and Clinical Gastroenterology. 2019;162(2): 151–158. (In Russ.) DOI: 10.31146/1682-8658-ecg-162-2-151-158
    Read & Download full text

    1. National Research OgarevMordovia State University, 430005, Saransk, Republic of Mordovia, Russia.

    Keywords: Remaxol, mechanical jaundice, hemostasis, endotoxicosis, lipid peroxidation, hypoxia

    Abstract:A study of 35 patients, whom operated by obstructive jaundice of neoplastic origin was done. They were divided into 2 groups: І (comparison groups, n = 15) — in the early postoperative period patients were given standard therapy and II (studied groups, n = 20) — Remaxol was included in the scheme of traditional treatment. In the study dynamics were carried out laboratory and biochemical tests: malonic dialdehyde (MDA) and diene conjugates (DC); phosphalipase A2 (PL A2); hypoxia ratio (HR); middleweight molecules (MWM), total (TAC) and eff ective albumin concentration (EAC), toxicity index (TI), total bilirubin (TB), alanine aminotransferase (ALT), activated partial thromboplastin time (APTT) and fi brinogen. Thromboelastography (USA) was used to assess the state of the hemostasis system. It was established that postoperative patients in the early time had oxidative stress, increased phospholipase activity, endotoxicosis syndrome, hemostatic disorders (hypercoagulation and hypofi brinolysis), which persisted throughout the observation period. The inclusion Remaxol in traditional therapy led to suppression of the intensity of lipid peroxidation (LP), reduction of phospholipase activity, relief of endogenous intoxication and hypoxia, restoration of blood coagulation-lytic status. The most signifi cant eff ect of the drug was determined in the fi rst 3 days after surgery. Objective: to evaluate the pharmacological eff ects of Remaxol in patients with mechanical jaundice of non-neoplastic origin.

      1. Belyaev A.N., Kostin S. V., Belyaev S. A., Tyurina N. A. Prevention of functional and structural disorders of the pancreas in acute obstructive cholestasis // Medical Almanac. 2018, No (52), pp. 59–63.
      2. Masyuk D. M. Kotik D. M., Kozlov V. G. Etiology of obstructive jaundice syndrome in patients with a history of cholecystectomy // Young Scientist. 2017, No 47 (181), pp. 181–184.
      3. Buslaeva E.S., Tarasova L. V., Matveeva, T. S. Hepatoprotectors in clinical practice. Algorithm selection // Health of the Chuvash Republic. 2015, No 2, pp. 56–64.
      4. Styazkina S.N., Gadelshina E. M., Voronchikhina E. M. Mechanical jaundice – the main complication of the hepatopancreatobiliary system // Science and Education Bulletin. – 2017. – V. 1. – № 5 (29). – P. 103–105.
      5. Styazhkina S.N., Nazhmudinova Z. Sh., Shamgunova I. I., Kaimova K. A. Comprehensive treatment of patients with obstructive jaundice syndrome // European Science. 2018, No. 2 (34), pp. 43–45.
      6. Tarasenko S.V., Zaitsev OV, Tyulenev D. O., Yudin V. A., Kopeikin A. A., Natalsky A. A., Bogomolov A. Yu., Kuznetsova A. S. Th e prevalence of complicated forms of gallstone disease // Science of the Young – Eruditio Juvenium. 2018. Vol. 6, No. 2, pp. 218–224.
      7. Shakhnazaryan N.G., Aydemirov A. N., Vafin A. Z., Shakhnazaryan A. M., Aydemirova E. A. A method for predicting the course of mechanical jaundice of various origins // Medical Journal of the North Caucasus. 2018, vol. 13, No. 2, pp. 370–373.

    Full text is published :
    Vlasov A. P., Al-Kubaisi Sh-A. S., Sheyranov N. S., Markin O. V., Zaitsev P. P., Vlasova T. I., Vasiliev V. V. Clinical examples to the algorithm on management of primary patients with symptoms of dyspepsia. Experimental and Clinical Gastroenterology. 2019;162(2): 159–164. (In Russ.) DOI: 10.31146/1682-8658ecg-162-2-159-164
    Read & Download full text